Scholar
Marketplace
Lab
Feedback
$
English
Sign In
Home
Search
My boards
Insights
Collaborators
Reader
Blog
Help
Home
Search
My boards
Insights
Collaborators
Reader
Blog
Help
Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma.
Translate
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Български
Catalan
Cebuano
中文(简体)
中文(繁體)
Corsican
Czech
Danish
Dutch
English
Esperanto
Estonian
Finnish
Français
Georgian
Deutsch
Greek
Haitian Creole
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Kazakh
Khmer
Korean
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malay
Maltese
Maori
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Romanian
Russian
Samoan
Serbian
Sinhala
Slovak
Slovenian
Somali
Spanish
Swahili
Swedish
Tajik
Tamil
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Xhosa
Zulu
Zhe Zhang
Nathalie Wong
Chit Chow
Anthony Chan
Edith Tin
Charing Chong
Journal:
2019/June
-
Journal of Pathology
ISSN:
1096-9896
PUBMED:
31168847
DOI:
10.1002/path.5313
Abstract:
Lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC) is a distinct variant of HCC that is characterized by dense tumor-infiltrating lymphocytes (TILs). Patients with LEL-HCC also show better clinical outcomes compared to conventional HCC (c-HCC), which is commonly presented with low TIL. Emerging evidence has begun to highlight tumor-intrinsic genetic abnormalities in the tumor-host immune interfaces. However, genome-wide characterization of LEL-HCC remains largely unexplored. Here, we defined the genomic landscape of 12 LEL-HCC using whole-exome sequencing, and further underpinned those genetic alterations related to an immune active microenvironment by comparing findings to 15 c-HCC that were sequenced in parallel. Overall, the mutational load between LEL-HCC and c-HCC was similar. Interestingly, SNV incidences of specific genes (CTNNB1, AXIN1, NOTCH1, and NOTCH2) were significantly higher in c-HCC than LEL-HCC, suggesting a plausible link between activated Wnt/β-catenin and Notch signaling pathways and immune avoidance. Marked focal amplification of chromosome 11q13.3 was prevalent in LEL-HCC. Using The Cancer Genome Atlas dataset, we further established oncogenes expressed from chromosome 11q13.3 (CCND1, FGF19, and FGF4) to be strongly associated with the immune checkpoint signature (CD274, PDCD1, BTLA, CTLA4, HAVCR2, IDO1, and LAG3). Our results have illustrated for the first time the somatic landscape of LEL-HCC, and highlighted molecular alterations that could be exploited in combinatory therapy with checkpoint inhibitors in targeting HCC. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Open in
PUBMED
|
DOI
|
Google Scholar
|
Wikipedia
Relations:
Citations
(4)
Diseases
(1)
Genes
(15)
Processes
(3)
Anatomy
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.
Drag-and-drop any entity to your messages.
Learn More
Search and select entities to see details here. Details will include lists of related entities (via publication). Explore related entities further.
Learn More